http://orcid.org/0000-0003-4300-5293
Figures
Abstract
Objective
Thrombophilic risk factors (TRFs) occur rather frequently in hemodialysis (HD) patients. However, little is known about their significance in HD patients, besides their potential impact on arteriovenous (AV) access failure, with varying results. We examined the effects of a wide variety of TRFs on both early AV fistula occlusion and survival among HD patients in long-term follow-up.
Methods
In this single-center, observational study, 70 consecutive HD patients from our dialysis center were examined with respect to shunt occlusion within the first 2 years after fistula creation and patient survival in a long-term follow-up (at least 16 years). We examined the presence of factor V, prothrombin, and MTHFR mutations using real-time fluorescence polymerase chain reaction. Furthermore, antithrombin (AT), protein C, protein S, and antiphospholipid antibodies (APL-Abs) were assessed.
Results
Among the 70 patients, 32 had MTHFR mutations, 10 had heterozygous factor V Leiden mutations, 4 had prothrombin mutations, 4 had protein S deficiency, 2 had protein C deficiency, 9 had AT deficiency, and 14 had APL-Abs. 40 patients had shunt occlusion. TRFs were associated with a significantly increased risk for shunt thrombosis (P<0.02). Kaplan–Meier analysis with a log-rank test revealed significantly shorter survival in HD patients with TRFs (P<0.02). Cox regression analysis showed that the presence of TRFs (P<0.05; hazard ratio, 1.94; 95% CI: 1.07–3.56), but not early shunt occlusion, was associated with short patient survival.
Citation: Grupp C, Troche-Polzien I, Stock J, Bramlage C, Müller GA, Koziolek M (2019) Thrombophilic risk factors in hemodialysis: Association with early vascular access occlusion and patient survival in long-term follow-up. PLoS ONE 14(9): e0222102. https://doi.org/10.1371/journal.pone.0222102
Editor: Maria Lourdes Gonzalez Suarez, University of Missippi Medical Center, UNITED STATES
Received: April 21, 2019; Accepted: August 21, 2019; Published: September 20, 2019
Copyright: © 2019 Grupp et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data cannot be shared publicly because of confidential patient data. Data are available from the Department of Nephrology and Rheumatology, Georg August-Universtity Göttingen, Germany, for researchers who meet the criteria for access to confidential data. Interested researchers may request data access by e-mail: nephrorheuma@med.uni-goettingen.de.
Funding: The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
In the general population, thrombophilic risk factors (TRFs) have been reported to be associated with increased mortality, presumably because of venous thromboembolism and associated complications [1–3]. Although TRFs occur even more frequently in hemodialysis patients than in the general population [4–7], little is known about their consequences in this patient group. In particular, information regarding the effects of TRFs on patient survival is lacking. TRFs have been studied in hemodialysis patients, especially with respect to their significance for arteriovenous fistula (AVF) thrombosis [4–6, 8–13]. Failure of an AVF is a serious problem in hemodialysis (HD-) patients, and it represents a major cause of morbidity and hospitalization in this patient group. Therefore, it might have an impact on survival in these patients as discussed by Feldman et al. [14]. The reported 1-year occlusion rates of fistulas vary considerably, and occlusion rates of up to 60% have been reported [15–19]. Coagulation disorders might be of great importance; however, limited and conflicting data exist regarding their relevance [4–6, 8–13]. A better understanding of the relevance of TRFs both for AVF-failure and mortality may help in the development of procedures to reduce these risks.
Therefore, the present study aimed to evaluate the impact of a wide variety of TRFs in HD-patients on the early shunt occlusion rate within 2 years as a short-term effect and, to best of our knowledge for the first time, on patient survival as a long-term effect. The study also assessed whether early AVF occlusion is a significant risk factor for HD-patient survival.
Subjects and methods
Study population
The study included 70 outpatients (32 female and 38 male patients) on maintenance hemodialysis treatment at the dialysis unit of the Department of Nephrology in the University Hospital of Göttingen, Germany. The mean patient age was 61 years (range, 32–86 years), and the follow-up period was 16 years (2000–2016). Two patients were lost to follow-up.
Shunt surgery was performed by vascular surgeons at the surgical department in the university clinic. The first AVF was usually a Cimino–Brescia fistula in the forearm (radiocephalic AVF), and if this failed, a fistula was established at the upper arm (brachiocephalic AVF) (Table 1). Patients had neither AVG nor central dialysis catheters. The detailed history of each patient was explored, with particular focus on occlusion of vascular access and other thrombotic events.
The following comorbid conditions were evaluated at the beginning of hemodialysis: cardiovascular disease (stroke or coronary heart disease), malignancy, diabetes mellitus and previous venous thrombotic event (Table 1). During and shortly before the study there were no pregnancies, no patient took oral contraceptives or received estrogen therapy. No patient suffered from nephrotic syndrome. aPTT, INR and platelet count were regularly examined in all patients. No primary abnormalities were observed.
The study was approved by the local ethics committee of Georg-August-University Göttingen and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each participant prior to inclusion into the study.
Analysis of coagulation factors
Prothrombin (20210G>A), factor V Leiden (1691G>A), and MTHFR (677C>T) genotyping.
Genotyping was performed with real-time polymerase chain reaction (PCR) involving hybridization probes using Light Cycler (Roche Biochemica, Mannheim, Germany) for prothrombin (20210G>A), factor V Leiden (1691G>A), and MTHFR (677C>T) mutations, according to our previously published methods [20, 21].
Coagulation assays.
Venous blood was collected in 0.1-M buffered trisodium citrate (blood:citrate, 9:1). Two centrifugation steps (10 min at 3000 g) were performed in order to obtain platelet-poor plasma. The plasma was aliquoted, frozen, and stored at −20°C until use.
Antithrombin (AT) and protein C activities were determined using the Coamatic LR Antithrombin kit (Chromogenix, Milano, Italy) and the Immunochrom PC kit (Baxter AG, Vienna, Austria), respectively. The functional activity of protein S was determined using the protein S Reagent kit (Dade Behring, Marburg, Germany). The lower limits of the reference ranges for antithrombin, protein C, and protein S activities were 80%, 68%, and 55%, respectively. The anticoagulant response to the addition of activated protein C was detected using the Coatest APC Resistance V kit (Chromogenix, Milano, Italy). The results were expressed as the ratio (APCsr) of the clotting time of plasma with APC to that of plasma without APC. The normal APCsr range was 2.0 to 3.2. The presence of lupus anticoagulant was determined using LA 1 Screening Reagent and LA 2 Confirmation Reagent (Dade Behring). Anti-cardiolipin Abs (aCLs) were determined using an ELISA method (Synelisa Cardiolipin antibodies, Pharmacia & Upjohn, Freiburg, Germany; microplate reader, Tecan, Crailsheim, Germany). The cut-off values for IgG, IgM, and IgA aCLs were 12 GPLU/ml, 6 MPLU/ml, and 10 APL U/ml, respectively.
All functional coagulation assays were performed using an autoanalyzer system (BCS, Dade Behring).
Samples were always taken directly before dialysis.
Statistical analysis
A preliminary descriptive statistical analysis was performed for all variables. Simple chi-square tests were first used to indicate the univariate dependence between the response variable “thrombophilic risk factor” or “shunt” and the binary explanatory variables. The relationship between the binary response variable “shunt occlusion” and the available explanatory variables was modeled using logistic regression. Logistic regression models the logit transformation of the individual’s event probability “shunt = yes” as a linear function of the explanatory variables. Survival analysis was performed for the variable “time after shunt creation” using the common Cox F-test and log-rank test. The effect of TRFs and other parameters on survival and their potential interactions were examined using Cox regression with backward variable selection. For survival time analysis, patient data were analyzed using Kaplan–Meier estimates and the log-rank test. Patients who were alive and those without existing follow-up data were censored. We have mentioned the 95% confidence intervals (CIs). A P-value <0.05 was considered significant. The statistical software Statistica, version 13 (TIBCO Software Inc., Tulsa, OK) was used.
Results
Association of thrombophilic risk factors with arteriovenous fistula failure
Of the 70 HD-patients, 40 (57%) experienced at least 1 AVF occlusion and 24 (35%) had recurrent events within 2 years after the start of dialysis. Most occlusions (28%) occurred during the first month. Within the following 5 months, the occlusion rate decreased to 2% per month, and after 6 months, it decreased to approximately 0.6% per month (Fig 1).
Within the first month the occlusion rate was quite high and rapidly decreased during the following months.
Prior to dialysis 4 patients suffered from thrombosis, 2 of them experienced AVF-occlusion. All patients exhibited MTHFR-mutation, one of these with AVF-failure additionally prothrombin mutation.
At least 1 TRF was detected in 68.6% (48/70) of patients, and the frequencies of potential further risk factors for fistula failure are shown in Table 1. Shunt occlusion was noted in 66% of patients with a thrombophilic disorder, and this rate was significantly higher than that in those without a TRF (34.8%; P<0.02; odds ratio 3.85; CI: 1.18–12.84; relative risk 1.89; CI: 1.07–3.81; Fig 2A). A single TRF was detected in 40.0% (28/70) of patients, and among these patients, 64.3% (chi-square test P<0.05 vs. no TRF) experienced shunt occlusion. Conversely, multiple TRFs were noted in 28.6% (20/70) of patients, and among these patients, 70% experienced shunt occlusion (P<0.05 vs. no TRF). The various coagulation disorders are discussed in the following (Fig 2B, Table 2).
(A) Data of all patients with TRFs (TRF), those with 1 TRF (1 TRF), and those with multiple TRFs (>1 TRF) are shown. *P<0.05 by Fisher’s exact test and chi-square test vs. no TRF; n.s., Fisher’s exact test P>0.05. (B) Shunt occlusion rate for the respective TRFs exclusively (dark bars) or combined with at least 1 further TRF (light bars). Factor V, factor V Leiden mutation; MTHFR, MTHFR mutation; APL-Abs, antiphospholipid antibodies; Prot. C/S, protein S/protein C deficiency; AT-def., AT deficiency; Prothromb. Mut., 20210G>A mutation of the prothrombin gene.
Factor V Leiden mutation.
Ten (14.0%) patients were identified as heterozygous carriers of this mutation, and all exhibited a lower activated protein C resistance with a mean ratio of 1.62 (range, 1.49–1.80; reference range, 2.00–3.00). Eight patients experienced at least 1 occlusion of vascular access, and of 7 patients with a further TRF, 6 had shunt thrombosis.
Protein S/protein C deficiency.
In 3 of 4 (5.7%) patients with decreased protein S plasma levels, shunt occlusions were found. Three patients exhibited APC resistance owing to a heterozygous mutation of factor V Leiden. As a factor V mutation may interfere in the assessment of protein S, the diminished levels may be associated with this defect. Both patients with decreased protein C had shunt occlusion.
20210G>A mutation of the prothrombin gene.
In 3 of 4 (5.7%) patients with this mutation, shunt thrombosis was noted.
Antithrombin deficiency.
Nine (12.9%) patients showed AT deficiency. Low AT plasma levels (mean activity, 67%; range, 59–76%) were associated in 8 of 9 patients with shunt thrombosis.
Antiphospholipid antibodies.
Fourteen (20.0%) patients had antiphospholipid antibodies (APL-Abs; 7 patients with lupus anticoagulant, 6 patients with aCLs, and 1 patient with both APL-Abs; aCL-IgM mean activity, 14.7 MPLU/ml; range, 7.6–34.1 MPLU/ml; aCL-IgG mean activity, 13.8 GPLU/ml; range, 12.7–14.8 GPLU/ml). In 9 of these patients (4 with lupus anticoagulant, 4 with aCLs, and 1 with both APL-Abs), shunt occlusion occurred.
MTHFR mutation.
In 32 patients with MTHFR mutation (30 heterozygous and 2 homozygous), an occlusion rate of 66% (21/32) was observed, and the relative risk increased by a factor of 1.5 (P<0.05). In these patients, the plasma homocysteine level increased (without shunt occlusion, 29.9 μml/l; with shunt occlusion, 31.2 μmol/l; P = 0.84), while the levels of vitamin B12 and folic acid were within the reference ranges.
Examination of the influence of other factors on the shunt occlusion rate
Logistic regression analysis showed that the shunt occlusion rate was significantly higher when a TRF was present (P<0.01, Table 3). The shunt occlusion rate was also higher in older patients than in younger patients (P<0.01). We examined the effect of various factors on shunt occlusion also in univariate dependence by chi-square-test and paired t-test (age). Here we observed a significant effect of TRFs (P<0.02) and age (P<0.005) on shunt survival as well. No significant associations between the shunt patency rate and sex, diabetes mellitus, cerebral stroke, coronary heart disease, malignancy, previous venous thrombotic event or location of the fistula (forearm/upper arm) could be found (Table 1).
Thrombophilic risk factors and patient survival
With regard to the examination of survival rates, 2 out of 70 patients were lost to follow-up, as information about their status could not be obtained. 9 patients underwent kidney transplantation. After 16 years of follow-up 7 patients were alive, and of these, 5 had received a renal allograft.
Considering the impact of coagulation disorders on survival, the 2 patients (both with early shunt occlusion) who were alive and still on dialysis at the end of follow-up had no coagulation disorder. Of the 9 transplanted patients, 3 had no TRF, 4 had 1 defect, and the remaining 2 had more than 1 defect. At the end of follow-up, 5 transplanted patients were alive with a kidney graft (3 patients without a TRF and 2 patients with 1 TRF). The 2 surviving patients with 1 TRF (both with shunt occlusion) carried a MTHFR mutation (Table 4). A thromboembolic event, as a known cause of death, was observed only in 1 patient without any TRF. The patient died from pulmonary artery embolisms 69 months after the start of dialysis.
The effects on survival and the potential interactions of TRFs and early shunt occlusion within 2 years, as well as the parameters of age, sex, coronary heart disease, diabetes mellitus, stroke, and malignancy at the start of dialysis were examined using Cox regression with backward variable selection. Age at the start of dialysis was found to have a strong, significant impact on survival (P<0.001; hazard ratio, 1.06; CI: 1.03–1.06). Additionally, the presence of at least 1 TRF was associated with a reduced survival time (P<0.05; hazard ratio, 1.94; CI: 1.07–3.56). Besides a borderline significance for malignancy (P = 0.06; hazard ratio, 2.4; CI: 0.97–4.27), the other aforementioned parameters, including early shunt failure, did not show any significant effect.
In agreement with this finding, on comparing the survival time of the 30 patients without and that of the 40 patients with early shunt occlusion using Kaplan–Meier analysis with a log-rank test, no significant difference in survival time was observed (P = 0.54). This finding suggests that early shunt occlusion has no relevant effect on patient survival (Fig 3).
No significant difference is observed between the 2 groups (P = 0.63).
Conversely, Kaplan–Meier analyses with a log-rank test of patients without a TRF and those with TRFs showed a significantly shorter survival time in patients with a TRF (P<0.05). Additionally, survival was significantly shorter in patients with more than 1 TRF than in patients without a TRF (P<0.01) or those with 1 TRF (P<0.02), whereas there was no significant difference in survival between patients without a TRF and those with 1 TRF (P = 0.175) (Fig 4).
Patient survival duration is significantly shorter in patients with more than 1 TRF than in patients without a TRF (P<0.01) or 1 TRF (P<0.02); however, the difference between the latter patients is not significant (P = 0.175). Survival duration is significantly longer in patients without a TRF than in patients with a TRF (P<0.02; not shown).
On evaluating the effects of various TRFs in detail, we did not observe a significant effect of any single TRF on patient survival. However, survival was significantly shorter in patients in whom a MTHFR-mutation, a factor V mutation, or APL-Abs occurred together with at least 1 further TRF than in patients with no TRF (log-rank test P<0.02, P<0.05, and P<0.05, respectively), while survival time tended to be shorter in patients with AT deficiency and a further TRF than in patients with no TRF (P = 0.054). Kaplan–Meier estimates of the TRFs with the highest prevalence are shown in Fig 5.
(A) MTHFR: Survival tended to be shorter in patients with only a MTHFR mutation (MTHFR only) than in patients without a TRF, but without statistical significance, whereas survival was significantly shorter in patients with a further coagulation disorder (MTHFR + further TRF) than in patients without a TRF (P<0.02). (B) Factor V (FV) mutation: Survival was not significantly different between patients with only a FV mutation (FV only) and patients without a TRF, whereas survival was significantly shorter in patients with a further coagulation disorder (FV + further TRF) than in patients without a TRF (P<0.05). (C) Antithrombin (AT) deficiency: Survival was not significantly different between patients with only an AT deficiency (AT only) and patients without a TRF, whereas survival tended to be shorter in patients with a further coagulation disorder (AT + further TRF) than in patients without a TRF (P = 0.054). (D) Antiphospholipid (APL) antibodies: Survival tended to be shorter in patients with only APL antibodies (APL only) than in patients without a TRF, but without statistical significance, whereas survival was significantly shorter in patients with a further coagulation disorder (APL + further TRF) than in patients without a TRF (P<0.05).
In summary, our results suggest that TRFs have a significant impact on survival time, particularly when more than 1 TRF is present, irrespective of the underlying entity.
Discussion
Patients with endstage renal disease are in a substantial procoagulable state. Coagulatory activity is further stimulated by hemodialysis, accompanied for example by elevated levels of prothrombin fragments and thrombin anti-thrombin-complexes [25]. In this study, we focused on the role of various inherited and acquired TRFs in vascular access occlusion and patient survival.
Consistent with the results in other studies [4–7], the prevalence of TRFs was significantly higher among HD-patients in this study than among the general population [2, 22–24]. In particular, acquired or partially acquired TRFs were clearly enhanced (Table 1). The higher prevalence of AT, protein S, and protein C deficiencies in hemodialysis patients might be explained by increased inhibitor consumption owing to a state of increased coagulation activity resulting from chronic kidney disease (CKD) and dialysis. Ghisdal et al. [7] observed a higher prevalence of the aforementioned acquired TRFs in patients with stage V CKD than in the general population, and the prevalence was even higher in patients on hemodialysis or peritoneal dialysis. Moreover, Ghisdal et al. [7] found a significant drop in these TRFs almost to the values in the general population within 1 month after kidney transplantation. The relatively higher prevalence of inherited factor V Leiden and factor II mutations in this study when compared to that in other studies was presumably random, whereas the prevalence of MTHFR mutations was similar to that reported in the general population [13, 26, 27].
The primary shunt occlusion rate within the first 2 years of hemodialysis was well within the range reported by others [15–19]. In younger patients, we observed a higher shunt survival rate, which is consistent with the data reported by Rodriquez et al. [28].
Here, the presence of TRFs was a major risk factor for shunt patency. Only very few patients exhibited other thrombotic events, suggesting that these disorders may manifest in particular conditions, such as artificial AVFs. Our results are consistent with the findings in the study by Knoll et al. [6], where positive correlations were identified between the number of coagulation disorders and vascular access problems.
On examining the impact of a single TRF on shunt occlusion, we found a significant effect of the MTHFR C677T mutation, which is consistent with the result of the study by Fukasawa et al. [13]. However, in contrast to the findings of the study by Födinger et al. [29], we observed no significant difference in the homocystein level between patients with and those without shunt occlusion. In agreement with the findings of the study by Lee et al. [27], we detected no significant difference in the homocysteine level among the 3 MTHFR genotypes in patients with end-stage renal disease, which is considered to be relevant in the pathogenesis of MTHFR-related thrombotic events [30].
In patients with factor V Leiden, we observed a high shunt occlusion rate at a APC sensitivity ratio of 1.62, similar to the finding (ratio of 1.45) by Bremer and Schäfer [31], while Födinger et al. [11] did not find such an association; however, in this study, the ratio was 2.31.
Similar to the findings of the study by LeSar et al. [12], the presence of APL-Abs was a risk factor for arteriovenous access thrombosis. Valeri et al. [32] found no effect on AVF survival but noted shorter AV graft survival in patients with aCL-IgG.
In summary, we found that TRFs, irrespective of their entity, had a relevant impact on shunt survival.
As vascular access problems are associated with high morbidity [14], they might influence patient survival. An increased rate of AVF failure owing to TRFs could be of pathogenetic importance. In addition, TRFs are associated with high mortality in the general population [1–3]. To best of our knowledge, this is the first study to assess the effects of TRFs on HD-patient survival in a long-term follow-up and furthermore to assess whether early AVF occlusion is a significant risk factor for HD-patient survival. Although increased morbidity associated with vascular access problems has previously been suspected [14], we observed no significant effect of early shunt occlusion on patient survival. Conversely, we found significant effects of TRFs on patient survival, particularly with the presence of more than 1 TRF. The 2 surviving patients who were on hemodialysis after the observation period did not have coagulation disorders, just as 3 of the 5 patients with a kidney graft who were alive. The 2 surviving transplanted patients with TRFs showed MTHFR mutations.
The particularly high survival rate in patients with a kidney graft might be associated with the better overall survival of transplanted patients than dialysis patients [33]. An at least partial correction of acquired TRFs by renal transplantation, as reported by Ghisdal et al. [7], suggests that this phenomenon might also contribute to the improved survival of transplanted patients.
Our results suggest that TRFs have an important impact on the survival of HD-patients independent of early shunt failure. We could not find a significant effect of a single TRF on patient survival. Limitations of this study should be noted. The sample size of this study is moderate, similar to almost all studies in this field. This might explain why we could not find a significant effect of a single TRF on vascular access occlusion and patient survival. However, as outlined above, the prevalence of TRFs and comorbidities in this study were well within the range reported by other researchers for hemodialysis patients [4–6]. We refrained from showing dichotomized data of hypertension or smoking, as exposure to these factors can vary greatly from individual to individual. We therefore preferred to present the main consequences of these risk factors, coronary heart disease and stroke, which were as well in the range as reported by others [4–6]. Performing thrombophilia testing only once is also a limitation. Repeated testing for acquired hypercoagulabilty e.g. antiphosphospholipid antibodes at least after 12 weeks is recommended [34]. The proportion of HD-patients positive for antiphospholipid antibodies was also within the range reported by others for this patient group [10, 32, 35–38]. In summary, this suggests that we examined a quite representative group of HD-patients. It is also possible that acquired TRFs were elevated at the time of vascular access thrombosis but normalized at the time of measurement. If this was the case, it would further emphasize the relevance of these TRFs.
The observational design of this study is a further limitation. For example, it doesn’t adequately allow the evaluation of the role of antithrombotic agents. This would require a detailed specification of their application. We therefore refrained from listing them. So far, a positive effect of any antithrombotic therapy to increase the patency of AVF or transplants in the overall population of HD-patients has not been convincingly demonstrated [39–41].
The significant effects of TRFs observed in this population indicate that these factors are of clinical importance, although the reader should be aware of the wide CI. Thus, TRFs in HD-patients should be considered as important risk factors not only for shunt occlusion but also for shortened survival in these patients. To reduce these risks, this observational study could not provide an optimal strategy. For example, the role of antithrombotic therapies in this subgroup of patients should be clarified, as such an approach did not show any significant benefit in the total population of HD-patients, as previously described. Randomized trials are needed to definitively determine the indications and potential strategies of therapeutic interventions.
In conclusion, our results show that TRFs occur very frequently in HD-patients and have important effects on both early shunt occlusion and patient survival. Thus, TRFs have effects on morbidity and mortality in these patients, although early AVF-failure has no significant impact on patient survival. Our findings could provide a basis for the development of strategies to improve the negative effects of coagulation disorders in HD-patients.
Acknowledgments
We gratefully acknowledge support for the biochemical analysis of the coagulation disorders by Nicolas von Ahsen, MD, Department of Clinical Chemistry, Georg-August University Göttingen. We also gratefully acknowledge support for the statistical evaluation of the data by Xenia Schulz, MSc, Core Facility Medical Biometry and Statistical Bioinformatics, Department of Medical Statistics, Georg-August University Göttingen.
References
- 1. Osinbowale O, Ali L, Chi YW. Venous thromboembolism: a clinical review. Postgrad Med. 2010; 122: 54–65 pmid:20203456
- 2. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006; 4: 15 pmid:16968541
- 3. Reitsma PH. Genetics in thrombophilia. An update. Hamostaseologie. 2015; 35: 47–51
- 4. Salmela B, Hartman J, Peltonen S, Albäck A, Lassila R. Thrombophilia and arteriovenous fistula survival in ESRD. Clin J Am Soc Nephrol. 2013; 8: 962–968 pmid:23411429
- 5. Klamroth R, Orlovic M, Fritsche I, Seibt S, Seibt F, Wegscheider K, et al. The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation. Vasa. 2013; 42: 32–39 pmid:23385224
- 6. Knoll GA, Wells PS, Young D, Perkins SL, Pilkey RM, Clich JJ, et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005; 16: 1108–1114 pmid:15728780
- 7. Ghisdal L, Broeders N, Wissing KM, Mena JM, Wijns W, Pradier O, et al. Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation. Nephrol Dial Transplant. 2011; 26: 2700–2705 pmid:21285127
- 8. Palomo I, Pereira J, Alarcon M, Vasquez M, Pierangeli S. Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis. Nephron. 2002; 92: 957–958 pmid:12399653
- 9. Hojs R, Gorenjak M, Ekart R, Dvoršak B, Pečovnik-Balon B. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail. 2002; 24: 215–222 pmid:12071595
- 10. Adler S, Szczech L, Qureshi A, Bollu R, Thomas-John R. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol. 2001; 56: 428–434 pmid:11770794
- 11. Fodinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Horl WH et al. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant. 1996; 11: 668–672. pmid:8671856
- 12. LeSar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg. 1999; 189: 73–79 pmid:10401743
- 13. Fukasawa M, Matsushita K, Kamiyama M, Mikami Y, Araki I, Yamagata Z et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis. 2003; 41: 637–642 pmid:12612987
- 14. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996; 7: 523–535 pmid:8724885
- 15. Almasri J, Alsawas M, Mainou M, Mustafa RA, Wang Z, Woo K et al. Outcomes of vascular access for hemodialysis: A systematic review and meta-analysis. J Vasc Surg. 2016; 64: 236–243 pmid:27345510
- 16. Biuckians A, Scott EC, Meier GH, Panneton JM, Glickman MH. The natural history of autologous fistulas as first-time dialysis access in the KDOQI era. J Vasc Surg. 2008; 47: 415–421; discussion 420–421 pmid:18241764
- 17. Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis. 2002; 39: 92–101 pmid:11774107
- 18. Puskar D, Pasini J, Savic I, Bedalov G, Sonicki Z. Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis. Croat Med J. 2002; 43: 306–311 pmid:12035137
- 19. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int. 2002; 62: 1109–1124 pmid:12234281
- 20. von Ahsen N, Schutz E, Armstrong VW, Oellerich M. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A), and methylenetetrahydrofolate reductase (C677T) by real-time fluorescence PCR with the LightCycler. Clin Chem. 1999; 45: 694–696 pmid:10222362
- 21. von Ahsen N, Oellerich M, Schutz E. A method for homogeneous color-compensated genotyping of factor V (G1691A) and methylenetetrahydrofolate reductase (C677T) mutations using real-time multiplex fluorescence PCR. Clin Biochem. 2000; 33: 535–539 pmid:11124338
- 22. Huisman MV, Rosendaal F. Thrombophilia. Curr Opin Hematol. 1999; 6: 291–297 pmid:10468143
- 23. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost. 2007; 33: 563–572 pmid:17768688
- 24. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001; 344: 1222–1231 pmid:11309638
- 25. Ambuhl PM, Wuthrich RP, Korte W, Schmid L, Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant.1997;12(11): 2355–2364 pmid:9394323
- 26. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost. 1999; 81: 733–738 pmid:10365746
- 27. Lee HA, Choi JS, Ha KS, Yang DH, Chang SK, Hong SY. Influence of 5,10- methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease. Am J Kidney Dis. 1999; 34: 259–263 pmid:10430972
- 28. Rodriguez JA, Ferrer E, Olmos A, Codina S, Borrellas J, Piera L. [Analysis of the survival of permanent vascular access ports]. Nefrologia 2001; 21: 260–273 [Article in Spanish] pmid:11471307
- 29. Fodinger M, Horl WH, Sunder-Plassmann G. Molecular biology of 5,10- methylenetetrahydrofolate reductase. J Nephrol. 2000; 13: 20–33 pmid:10720211
- 30. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325: 1202 pmid:12446535
- 31. Bremer C, Schaefer RM. Heterozygosity for factor V Leiden in a haemodialysis patient with recurrent shunt thrombosis. Nephrol Dial Transplant. 1997; 12: 1775–1776 pmid:9269682
- 32. Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol. 1999; 51(2): 116–121 pmid:10069647
- 33. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011; 11: 2093–2109 pmid:21883901
- 34. Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2): 85–94 pmid:25025009
- 35. Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int. 1995;48(3): 794–800 pmid:7474666
- 36. Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995;26(2): 347–352 pmid:7645540
- 37. Chuang FR, Chen TC, Yang CC, Cheng YF, Hsu KT, Lee CH, et al. IgM-anticardiolipin antibody and vascular access thrombosis in chronic hemodialysis patients. Ren Fail 2005;27(1): 25–30 pmid:15717631
- 38. Chen TY, Lin L, Hsieh MY, Chen YF, Hsu KT, Lee CH. Thrombophilia Associated with Early Post-angioplasty Thrombosis of Dialysis Vascular Access. Cardiovasc Intervent Radiol 2018;41(11): 1683–1690 pmid:30066093
- 39. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 156: 445–459 pmid:22431677
- 40. Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;156(6):445–459 pmid:22431677
- 41. Tanner NC, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev 2015(7): Cd002786 pmid:26184395